Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy

Diabetes Care

Volumn 19, Issue 5, 1996, Pages 441-445

  Yokoyama, Hiroki ^a,c   Myrup, Bjarne ^a   Rossing, Peter ^a   Østergaard, Per B ^b  

^a STENO DIABETES CENTER   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; GLYCOPROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTHROMBIN; TISSUE FACTOR PATHWAY INHIBITOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD CLOTTING TIME; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030008230     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.5.441     Document Type: Article

References (32)

1. Broze GJ, Girard TJ, Novotony WF: Regulation of coagulation by a multivalent Kunitz type inhibitor. Biochemistry 29: 7539-7546, 1990
2. Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen PM, Moeller KB, Meidahl-Pedersen J, Beck TC, Norris K, Hedner U, Kisiel W: Recombinant human extrinsic pathway inhibitor: production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 265: 16786-16793, 1990
3. Wun TC, Kretzmer KK, Girard TJ, Meletich JP, Broze GJ: Cloning and characterization of a cDNA coding for the lipoprotein associated coagulation inhibitor shows that it consists three tandem Kunitz type inhibitory domains. J Biol Chem 263: 6001-6004, 1988
4. Girard TJ, Warren LA, Novotony WF, Likert KM, Brown SG, Miletich JP, Broze SG: Functional significance of the Kunitz type inhibitory domains of lipoprotein associated coagulation inhibitor. Nature 338:518-520, 1989
5. Lindahl AK, Sandset PM, Abildgaard U: The present status of tissue factor pathway inhibitor. Blood Coagul & Fibrinolysis 3:439-449, 1992
6. Broze GJ, Lange GW, Duffin KL, MacPhail L: Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul & Fibrinolysis 5:551-559, 1994
7. Leurs PB, van Oerle R, Hamulyak K, Wolffenbuttel BHR: Tissue factor inhibitor activity in patients with IDDM. Diabetes 44:80-84, 1995
8. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T: Features of endothelial dysfunction in early diabetic nephropathy Lancet i:461-463, 1989
9. Shimomura H, Spiro RG: Studies of macromolecular components of human basement membrane and alterations in diabetes: decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 36: 374-381, 1987
10. Jensen T, Stender S, Deckert T: Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion. Diabetologia 31:142-145, 1988
11. Feldt-Rasmussen B, Dinesen B, Deckert M: Enzyme immunoassay: an improved determination of urinary albumin excretion in diabetics with incipient nephropathy. Scand J Clin Lab Invest 45:539-544, 1985
12. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
13. Pelzer H, Schwarz A, Stuber W: Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemostasis 65:153-159, 1991
14. Kristensen HI, Østergaard PB, Nordfang O, Abildgaard U, Lindahl AK: Effects of tissue factor pathway inhibitor in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin. Thromb Haemostasis 68:310-314, 1992
15. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordoy A: Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb Vasc Biol 14 223-229, 1994
16. Nordfang O, Bjorn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U: The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 30 10371-10376, 1991
17. Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ: Anticoagulant activity of tissue factor pathway inhibitor is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb Vasc Biol 13:1066-1075, 1993
18. Mitropoulos KA, Miller GJ, Martin JC, Reeves BEA, Cooper J: Dietary fat induces changes in factor VII procoagulant activity through effects on plasma free stearic acid activation Arterioscler Thromb Vasc Biol 14:214-222, 1994
19. Silveira A, Karpe F, Blomback M, Steiner G, Walldius G, Hamsten A: Activation of coagulation factor VII during alimentary lipemia Arterioscler Thromb Vasc Biol 14: 60-69, 1994
20. van der vom JG, Bots ML, van Vliet HHDM, Hofman A, Grobbee DE: Factor VII coagulant activity is related to blood lipids in the elderly: The Rotterdam Study. Fibrinolysis 8 (Suppl. 2):132-134, 1994
21. Mitropoulos KA, Miller GJ, Reeves BEA, Wilkes HC, Cruickshank JK. Factor VII coagulant activity is strongly associated with plasma concentrations of large lipoprotein particles in middle aged men. Atherosclerosis 76:203-208, 1989
22. Sandset PM, Abildgaard U, Larsen ML: Heparin induces release of extrinsic coagulation pathway inhibitor. Thromb Res 50: 803-813, 1988
23. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ: Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples Blood 78: 387-393, 1991
24. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP: Cultured normal human haptocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis Proc Natl Acad Sci USA 87:8869-8873, 1990
25. Warn-Cramer BJ, Almus FE, Rapaport SI: Studies of the factor Xa-dependent inhibitor of factor VIIa/tissue factor (extrinsic pathway inhibitor) from cell supernates of cultured human umbilical vein endothelial cells. Thromb Haemostasia 61:101-105, 1989
26. Rapaport SI: The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemostasis 66:6-15, 1991
27. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ: Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul & Fibrinolysis 4:661-669, 1993
28. Ratz I, Havivi Y, Yarom R: Reduced negative surface charge on arterial endothelium of diabetic rats. Diabetologia 31:618-620, 1988
29. Rohrbach DH, Wagner CW, Star VL, Martin GR, Brown KS, Yoon JW. Reduced synthesis of basement membrane heparan-sulfate proteoglycan in streptoxotocin-induced diabetic mice. J Biol Chem 258:11672-11677, 1983
30. Kario K, Matsuo T, Yamada T, Matso M: Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemostasis 71 275-279, 1994
31. Ostermann H, van de Loo J: Factors of the hemostatic system in diabetic patients a survey of controlled study. Haemostasis 16:386-416, 1986
32. Ceriello A: Coagulation activation in diabetes mellitus: the role of hyperglycemia and therapeutic prospects Diabetologia 36:1119-1125, 1993